The Bergen 4-Day Treatment (B4DT) for Obsessive-Compulsive Disorder: Outcomes for Patients Treated After Initial Waiting List or Self-Help Intervention

Gunvor Launes1,2, Kristen Hagen3,4*, Lars-Göran Öst3,5, Stian Solem3,6, Bjarne Hansen3,7 and Gerd Kvale2,3

1 Sørlandet Sykehus, Kristiansand, Norway, 2 Department of Clinical Psychology, University of Bergen, Bergen, Norway, 3 Bergen Center for Brain Plasticity, Haukeland University Hospital, Bergen, Norway, 4 Møre and Romsdal Hospital Trust, Molde, Norway, 5 Department of Psychology, Stockholm University, Stockholm, Sweden, 6 Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway, 7 Center for Crisis Psychology, Faculty of Psychology, University of Bergen, Bergen, Norway

The Bergen 4-day treatment (B4DT) for obsessive-compulsive disorder (OCD) was recently tested in a randomized controlled trial, where the results showed that the B4DT was more effective than a self-help intervention (SH) and a waiting list condition (WL). Patients in the SH and WL condition still in need of treatment after the first intervention (N = 26; 13 from each condition) were offered the B4DT. None of the patients declined participation, and there were no dropouts. At post-treatment 59.5% were in remission, 31.0% had treatment response, and 9.5% showed no change. At 3-month follow-up 71.4% were in remission, 19.0% had treatment response, and 9.5% showed no change. There were also significant improvement in self-reported symptoms of OCD, generalized anxiety symptoms, and depressive symptoms. The results are in line with what we previously have found for the B4DT in a number of effectiveness studies. In addition, the results indicate that the patients who previously had received an unsuccessful SH intervention and patients who had first been in a WL condition, profited as much as patients who had received the B4DT as the initial intervention. Implications for clinical guidelines and for dissemination of the B4DT are discussed.

Keywords: obsessive-compulsive disorder, ERP, RCT, B4DT, self-help, waiting list, follow-up

INTRODUCTION

Obsessive-compulsive disorder (OCD) is a disabling disorder characterized by recurrent, unwanted thoughts, images, or urges (obsessions) and/or repetitive behaviors or thoughts (compulsions) (American Psychiatric and Association, 2013). Cognitive behavioral therapy (CBT) with exposure and response prevention (ERP) is a well-established treatment for patients with OCD (Rosa-Alcázar et al., 2008; Öst et al., 2015). Meta-analyses (e.g., Öst et al., 2015) of randomized controlled trial (RCT) suggest that approximately 65% of patients achieve a reliable treatment response
and 50% are in remission following treatment. Treatment can be given individually and in groups and with different intensity and the results are quite similar (Rosa-Alcázar et al., 2008; Olatunji et al., 2013; Øst et al., 2015). Several studies suggest that intensive (in- and outpatient) treatment could be effective in treating adults with OCD (Jónsson et al., 2015; Veale et al., 2016), but also for children with anxiety (Øst and Ollendick, 2017). These treatments are, however, often not available for the patients (Shafran et al., 2009). The National Institute for Health and Care Excellence (NICE, 2005) thus recommends a stepped care model where the first intervention is “brief individual CBT (including ERP) using structured self-help materials” since these approaches can be easily disseminated. Self-help interventions are documented effective, although with smaller effect sizes than face-to-face treatment (Peirce et al., 2016).

Since 2012, the OCD-team in Bergen, Norway, has developed a highly concentrated exposure based treatment format for patients with OCD, the Bergen 4-day treatment (B4DT). During four consecutive days, OCD patients receive individually tailored and therapist assisted exposure treatment delivered in a group setting, where the patient-therapist ratio is 1:1. The approach is highly attractive to the patients, and there is basically no attrition. A number of open trials indicate that more than 90% of the patients can expect to respond to treatment within 70% being recovered 1–4 years after participating in the B4DT (Hansen et al., 2018, 2019). The B4DT has also been piloted outside the Bergen group (Kvale et al., 2018; Launes et al., 2019a,b), and in a different country (Davíðsdóttir et al., 2019), with the same results.

Recently, the first randomized controlled trial (RCT) of the B4DT was completed (Launes et al., 2019b), where it was compared to a self-help (SH) intervention as well as a waiting list (WL) condition. Results showed that 93.8% responded to treatment in the B4DT condition. For patients in the SH condition, 12.5% responded, while none of the patients on WL had a treatment response. At 3-month follow-up, 69% were remitted and 31% were improved. At 6-month after treatment, 81% were in remission, 6% were improved, and 13% unchanged. Thus, the first controlled trial of the B4DT supported the positive findings from the open trials.

The patients who were in need of further treatment after the SH or WL condition were offered the B4DT, which implies that for the patients who first received the SH, the National Institute for Health and Care Excellence (NICE, 2005) guidelines of a stepped care approach were followed. Clearly, the NICE recommendations assume that patients who have first received unsuccessful SH are not at a disadvantage when they proceed to a therapist-assisted intervention, but the documentation for this is sparse. Thus, in the current article we will investigate the following questions: (1) Are clinical changes after the B4DT also seen in the patients with prior experience of SH or a WL, and are the changes maintained at 3-month follow-up? (2) Do the patients who had received an unsuccessful SH treatment profit as much as patients who had received the B4DT as the initial intervention?

METHODS

Participants and Design

From 2016 to 2017 a randomized controlled trial (RCT) was conducted at Solvang Community Psychiatric Service (Sørlandet Hospital) in Norway (Launes et al., 2019b). The RCT compared the effects of B4DT to the effects of a SH intervention and a WL. Included participants consisted of consecutive referrals to a specialized OCD-team at the hospital. Patients were referred from their general practitioner or their local outpatient clinic. Referrals were based upon a suspicion of OCD.

The inclusion criteria for the study were: (a) signed informed consent, (b) ≥18 years, (c) met DSM-5 criteria for OCD, (d) Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score ≥16, and (e) spoke Norwegian fluently. The exclusion criteria for the study were: (a) meeting DSM-5 criteria for bipolar disorder, psychosis, or ongoing substance abuse/dependence, (b) intellectual disability based on previous medical history, (c) an eating disorder in need of medical attention, (d) not willing to refrain from anxioylitics during treatment, (e) ongoing suicide ideation, (f) SSRI-treatment initiated or dosage changed during the last four weeks before starting treatment, and (g) living far away from the treatment center (>1.5 h). Patients with prior CBT for OCD were not included due to a nationwide trial targeting this population. The patients who were not helped after a SH condition or a WL were offered the B4DT (Launes et al., 2019b). A flow-chart of the study is presented in Figure 1.

Two of the patients who had received the SH intervention had improved according to their own evaluations and did not want further treatment and one patient who had received SH moved to another part of the country. Thus, 13 patients in the previous SH condition started treatment with the B4DT. Of the 15 patients who previously completed the WL condition, one moved to another part of the country, and another received inpatient treatment due to pregnancy complications, leaving 13 patients who started the B4DT. All patients who had received B4DT as the immediate intervention (n = 16) function as a comparison condition at follow-up. The 26 patients who had received either WL or SH condition were assigned to the first available B4DT group.

Background Data

Table 1 displays a summary of the participants’ demographic data, diagnostic information and pharmacological treatment. There was no difference in pre-treatment Y-BOCS scores between patients who had previously been in the SH or the WL condition, F(1,24) = 0.121, p = 0.731. In addition, there were no significant differences between these two groups on any other pre-treatment variable. All patients but one were classified as having severe OCD (Y-BOCS score of 24 or more) at pre-treatment.

The patients’ use of medication was recorded at the initial interview. Patients using benzodiazepines discontinued these prior to treatment. Compliance was confirmed in the post-treatment assessment. Patients had no other treatment during the four days, as confirmed by medical records.
Assessment
Patients had a diagnostic- (First et al., 2015) and Y-BOCS interview with an independent assessor by phone one week prior to starting treatment. Patients were re-assessed by an independent assessor within one week after completing treatment and at 3-month follow-up. For further procedural details regarding the RCT, please refer to Launes et al. (2019b). Following the assessment after three months of SH or WL, patients who wanted further treatment were offered participation in a B4DT group. The assessment procedures were the same for the patients that first received SH or WL. Inter-rater reliability was checked with respect to OCD diagnosis and Y-BOCS. For the OCD diagnosis the kappa value was 1.00, while the intra-class correlation for Y-BOCS was 0.97.

Measures
OCD symptoms
The Y-BOCS (Goodman et al., 1989a,b) is a 10-item interview, and was used as the primary outcome measure in this study. Ten items are rated on a 0–4 scale, and total score
TABLE 1 | Background characteristics of the combined waiting list- and self-help condition \( (N = 26) \).

|                        | \( M (SD) \)    |
|------------------------|-----------------|
| Age                    | 28.08 (6.69)    |
| Age of OCD onset       | 13.19 (7.44)    |
| Number of comorbid disorders | 2.65 (1.50)   |

|                        | \( N \) (%)    |
|------------------------|----------------|
| Females                | 21 (80.8)      |
| Single                 | 13 (60.0)      |
| Student                | 5 (19.2)       |
| Employed               | 9 (34.6)       |
| On social benefits     | 12 (46.2)      |
| OCD in the family      | 8 (30.8)       |
| Psychotropic medication| 11 (42.3)      |
| Any comorbid disorder  | 24 (92.3)      |
| Comorbid depression    | 14 (53.8)      |
| Comorbid anxiety       | 16 (61.5)      |
| Other comorbidity      | 10 (38.5)      |

Three patients had five comorbid disorders, six had four, four had three, seven had two, and four patients had one comorbid disorder. The "other comorbidity" category included bulimia, insomnia, ADHD, and skin picking. There were no significant differences between the SH and WL group on these variables, except for "other comorbidity" where the WL group had slightly more disorders than the SH group (\( \chi^2 = 5.85, p = 0.016 \)).

Ranges from 0 to 40. Psychometric properties are good (Goodman et al., 1989a,b).

Two self-report measures of OCD symptoms were also included. The Dimensional Obsessive Compulsive Scale Short-Form (DOCS-SF; Eilertsen et al., 2017) is a five item version of the original 28-item version of DOCS (Abramowitz et al., 2010). The five items are rated on a scale from 0 to 8 and concern time spent, avoidance, distress, interference with functioning, and difficulty disregarding obsessions and refraining from compulsions. The total score ranges from 0 to 40.

The second self-report measure of OCD symptoms was the Obsessive-Compulsive Inventory-Revised (OCI-R; Foa et al., 2002), an 18-item scale. Items are rated on a 0–4 scale, and total score range from 0 to 72. The OCI-R has good psychometric properties (Foa et al., 2002; Solem et al., 2010).

In addition to measures of OCD-symptoms, the study included measures of comorbid symptoms of depression and generalized anxiety. The Patient Health Questionnaire-9 (PHQ-9; Kroenke et al., 2010) is a 9-item scale assessing symptoms of depression. Items are rated on a 0–3 scale, and total score ranges from 0 to 27. The PHQ-9 has sound psychometric properties (Kroenke et al., 2010).

The Generalized Anxiety Disorder Scale (GAD-7; Spitzer et al., 2006) is a 7-item scale assessing symptoms of generalized anxiety. Items are rated on a 0–3 scale, and total score ranges from 0 to 21. Psychometric properties of the GAD-7 are good (Spitzer et al., 2006; Beard and Bjorgvinsson, 2014; Rutter and Brown, 2017).

In addition to the symptom scales, we also included a measure of satisfaction with treatment. The Client Satisfaction Questionnaire 8 (CSQ-8; Nguyen et al., 1983) is an 8-item scale assessing satisfaction with treatment received. Items are rated on a 0–4 scale, and total score ranges from 8 to 32. Psychometric properties of the CSQ-8 are good (Larsen et al., 1979; Nguyen et al., 1983).

**Therapists**

There were equal number of patients and therapists in each group, and each group was led by an expert on the treatment format. All therapists were trained in delivering the treatment (Kvale and Hansen, 2014). Prior to acting as a B4DT therapist, each had been evaluated as competent by two independent assessors in a minimum of two B4DT groups. Specific competencies in conducting the LET-intervention (see below) were evaluated by a B4DT expert watching videotaped sessions. The leaders of the groups had participated as therapists in at least six B4DT groups in order to be certified as competent. Then they acted as leaders of a minimum of two B4DT groups prior to the trial. Therapists in the present study included five psychologists, two psychiatric nurses, and two psychiatrists.

**The B4DT Format**

A detailed description of the treatment format is given in Launes et al. (2019b). Prior to the treatment, the patients were provided with oral and written information about the content of the four days.

**The LET-Technique**

Prior to exposure treatment, patients are taught to pay close attention to the way the exposures are done, and one of the main features of the 4-day treatment, namely the “LEan into The anxiety” (LET-technique) is demonstrated. Patients have to approach stimuli that elicit anxiety/discomfort and act in a manner that is incompatible with their OCD. During the two days of exposure treatment, the patients are assisted when they practice the LET-technique, and encouraged and assisted to employ the approach in all situations that elicit anxiety/discomfort.

**Day 1, Psychoeducation and Treatment Preparation (3–4 h)**

Participants receive psychoeducation in which they are provided with explanations for the treatment and for the techniques that are seen as essential. The psychoeducation is manualized using a PowerPoint presentation with a text-file detailing the content to be presented. The patients share their suggested exposure tasks with the group, and individual plans are made together with input from the group leader.

**Day 2 and 3, (8 h + 1.5 h Psychoeducation for Family)**

Throughout Day 2 and 3, patients practice individually tailored and therapist assisted ERP. In the evening patients are to continue with self-administrated training. Exposure sessions are interspaced with brief group meetings where each patient share their ratings of their own exposure performance with the group. They evaluate their own LET-performance on a 1–6 scale. A score of 6 indicates that they were “leaning fully into” the anxiety. Scores below 6 are explored by the group leader, and the patients are given advice and encouragement aimed at giving them courage to “not hold back” in the next exposure. Patients
were given the opportunity to invite relatives and friends to a psychoeducation session in the afternoon of day 3.

**Day 4, Summarizing and Relapse Prevention**
Day 4 is used for summarizing and planning self-exposures for the next three weeks. Patients are taught to be their own therapists. They make their own exposure plans to be performed the first three weeks after the treatment. Written information concerning procedures and upcoming assessments is handed out, and the group ends with the patients providing feedback on their experiences with treatment.

**Homework Assignments and Follow-Up Visit**
Patients log homework (exposures) completed for a 3-week period after treatment. About 12 weeks after treatment, patients meet for an individual follow-up session at the clinic. This session is intended to help the patient summarize their experiences after completing treatment, and if necessary, to refresh the treatment principles. This follow-up session did not involve exposure exercises.

**Classification of Treatment Response and Remission**
An adaptation of the international consensus criteria was used for assessing treatment response (Mataix-Cols et al., 2016), not including the criterion for change in Clinical Global Impression. A treatment response involves a ≥35% reduction in Y-BOCS score. Remission is defined as meeting the treatment response criterion as well as having a post-treatment or follow-up Y-BOCS score of 12 or less.

**Statistical Analysis**
There were few instances of missing data. For Y-BOCS and the self-report scales there were four patients missing data at post-treatment-2. However, all four patients attended the follow-up assessment, and their scores from follow-up were therefore carried backward to replace their missing post-treatment-2 score. Imputation using “next observation carried backward” is one of the imputation methods giving least bias in scores (Mundahl Engels and Diehr, 2003). There was only one patient missing self-report data at follow-up. This patient was given his/her post-treatment score as follow-up score (last observation carried forward). One patient had missing data on the CSQ-8, which was not replaced.

Paired sample t-tests were first used to investigate if the SH or WL groups had any significant improvement on Y-BOCS scores (post-treatment-1). Paired sample t-tests were also used to investigate whether the two groups had a significant improvement after being given the B4DT at post-treatment-2 and 3-month follow-up. Independent sample's t-tests were used to compare the two groups at post-treatment-2 and follow-up. Possible differences in change scores (from pre-treatment to post-treatment-2 and follow-up) between participants given immediate B4DT and delayed B4DT were also compared using independent samples t-tests.

Treatment outcome was further analyzed using repeated measures ANOVA with three different times of assessment (pre-treatment, post-treatment, and follow-up). This analysis was used for all outcome measures (Y-BOCS, PHQ-9, GAD-7, OCI-R, and DOCS-SF).

**RESULTS**
A summary of the Y-BOCS scores for the SH- and WL-conditions is displayed in Table 2. Paired sample t-tests showed that there was no significant effect of the WL at post-treatment-1, while there was a significant but small improvement observed for the SH-condition. The patients then received the B4DT after the post-treatment-1 assessment. Irrespective of which original condition the patients belonged to they achieved a very large and significant improvement at the post-treatment-2 assessment. The change scores (pre-treatment to post-treatment 2/follow-up), was not significantly different between the conditions at post-treatment 2; t(24) = 0.164, p = 0.871, or at follow-up; t(24) = 0.35, p = 0.73. Participants from the two groups were therefore merged together into one group for further analyses.

Change in Y-BOCS scores after being given the B4DT was compared between patients given immediate B4DT (N = 16) and patients originally in the SH or WL condition (N = 26). The immediate B4DT group had a mean change score of 15.85 (5.85) at post-treatment compared to 16.31 (4.52) for the SH/WL patients, t(40) = 0.287, p = 0.775. There were also a non-significant difference at follow-up, as immediate B4DT showed a mean change score of 18.19 (5.95) compared to 17.58 (7.18) for the WL/SH group, t(40) = 0.285, p = 0.777. Thus, for the analysis of clinical change all patients were combined into

| TABLE 2 | Y-BOCS means (SDs) for the two groups at the four assessment points. |
|----------|-------------------|---------|---------|---|---|---|---|
|          | Pre | Post-1 | Post-2 | 3m F-U | Pre–Post-1 | Pre–Post-2 |
| Y-BOCS M (SD) | t   | p      | t      | p   | t     | p     |
| Immediate B4DT (n = 16) | 26.75 (4.23) | 10.90 (4.35) | 8.56 (5.75) | 0.39 | 0.71 | 12.87 | <0.0001 |
| WL (n = 13) | 27.08 (3.59) | 26.77 (4.04) | 10.62 (2.22) | 10.00 (5.85) | 0.287 | 0.775 | 12.62 | <0.0001 |
| SH (n = 13) | 29.15 (3.46) | 26.85 (3.26) | 12.99 (3.59) | 11.08 (6.09) | 2.93 | 0.01 | 12.62 | <0.0001 |

Y-BOCS, Yale-Brown Obsessive Compulsive Scale; B4DT, Bergen 4-day treatment; WL, waiting list; SH, self-help; Pre, pre-treatment; Post-1, post-treatment after WL or SH; Post-2, post-treatment after B4DT; 3m F-U, 3-month follow-up after B4DT.
Clinically Significant Change in OCD-Severity

The clinical improvements at post-treatment and follow-up are presented in Table 3. Of the 42 patients given the B4DT, 25 (59.5%) were remitted at post-treatment, 13 (31.0%) had a treatment response, and 4 (9.5%) showed no change. At 3-month follow-up 30 patients (71.4%) were remitted, 8 (19.0%) had a treatment response, and 4 (9.5%) showed no change. The 25 patients classified as remitted at post-treatment had a stable improvement as 24 (96%) were still remitted at follow-up, while one patient was now classified as a treatment responder. In other words, there were no clear signs of relapse. There were 13 patients classified as having treatment response at post-treatment, and of these five (38%) achieved remission at follow-up, five remained responders, while three showed no change at follow-up. Four patients were classified as having no change at post-treatment, and of these one patient achieved remission at follow-up, two were classified as treatment responders, and one was still classified as having no change. No patients deteriorated.

Secondary Outcome Measures

Table 4 displays the results for Y-BOCS and secondary outcome measures at pre-treatment, post-treatment, and 3-month follow-up. Repeated measures ANOVA found a significant effect of time for all five measures. The effect size was highest for change in OCD measures and lowest (but moderate) for change in depression.

Additional Analyses

Patients using psychotropic medication did not differ on OCD-severity at pre-treatment, \( t(24) = 0.33, p = 0.74 \), from those not taking such medication. However, they showed tendencies toward having higher Y-BOCS scores at post-treatment (\( M = 13.2, SD = 4.0 \) vs. \( M = 10.8, SD = 1.9 \)) and follow-up (\( M = 13.0, SD = 6.6 \) vs. \( M = 8.7, SD = 4.8 \)), \( p = 0.048 \) and \( p = 0.066 \), respectively. Similar observations were made for the DOCS-SF data, but not for the other outcome measures (PHQ-9, GAD-7, and OCI-R). There were no significant differences in client satisfaction scores, \( t(22) = 0.09, p = 0.93 \).

Treatment Satisfaction

Data on treatment satisfaction is presented in Table 5. The majority (96%) were happy with the quality of service, and all participants would have recommended it to a friend with a similar condition. All participants also rated the overall satisfaction with the treatment as positive. The mean satisfaction score of 28.96 (SD = 3.06) was comparable to patients in the immediate B4DT condition who scored 29.69 (SD = 2.62), a non-significant difference.

DISCUSSION

The present study was a follow-up of a recently conducted RCT for OCD where the experimental group was treated with the newly developed B4DT and the two control conditions consisted of patients that either were allocated to SH or WL. The results from the controlled trial (Launes et al., 2019b) showed that compared to SH- and WL-participants the patients in the B4DT reported significantly lower scores on OCD severity, depression,
first step affected treatment response in step 2. A somewhat
discouraging, however, it is difficult to conclude whether the
response rate of 43% for ITT). Results from step 2 was somewhat
after step 1, while only one patient responded at follow-up (total
directed ERP (step 2). In that study, five patients responded
the first step of treatment, and step 3 was traditional therapist
minimal therapist contact (step 2) if they did not respond to
received SH (step 1), followed by self-directed ERP with
attrition issues. In a pilot study of stepped care, 11 patients
OCD-, depression- and general anxiety symptoms. There were
maintained and slightly improved at the 3-month follow-up, with
Overall, treatment gains made from pre- to post-assessment were
immediately. At post-treatment and follow-up 90.5% showed
a treatment response, and the remission rates were 58% at
post-treatment and 73.1% at follow-up. This corresponds well
with previous research on the B4DT (e.g., Kvale et al., 2018).
Overall, treatment gains made from pre- to post-assessment were
maintained and slightly improved at the 3-month follow-up, with
no difference between the conditions in terms of reduction of
OCD-, depression- and general anxiety symptoms. There were
also no differences in experienced satisfaction with the B4DT
even for the patients that first had been on a WL or participated
in a SH program for OCD.

There are only three studies investigating the effect of stepped
care treatment for OCD, and they suffer from sample size and
attrition issues. In a pilot study of stepped care, 11 patients
started with SH (step 1), followed by self-directed ERP with
minimal therapist contact (step 2) if they did not respond to
the first step of treatment, and step 3 was traditional therapist
directed ERP (Tolin et al., 2005). Of the 11 who started treatment
two patients responded after step 1, two responded after step 2,
and two responded after step 3 (total of 6 responders, 55% of
ITT). Gilliam et al. (2010) also published a small open trial of
stepped care treatment for 14 patients with OCD. Participants
first received self-directed ERP (step 1) followed by therapist-
directed ERP (step 2). In that study, five patients responded
after step 1, while only one patient responded at follow-up (total
response rate of 43% for ITT). Results from step 2 was somewhat
discouraging, however, it is difficult to conclude whether the
first step affected treatment response in step 2. A somewhat

generalized anxiety, as well as higher social and work-related
functioning, at post-treatment. The patients who were in need
of further treatment after SH or WL were offered B4DT, and the
aims of the present study were to investigate if the clinical changes
after B4DT are also seen in patients with prior experience of SH
or a WL, and if patients who had received an unsuccessful SH
treatment improved as much as patients who had received the
B4DT as the initial intervention.

The results indicate that both the patients who had previously
received SH and those in the WL condition benefited significantly
from the B4DT, and that they did not differ in treatment effect at
3-month follow-up from the patients who had received the B4DT
immediately. At post-treatment and follow-up 90.5% showed
a treatment response, and the remission rates were 58% at
post-treatment and 73.1% at follow-up. This corresponds well
with previous research on the B4DT (e.g., Kvale et al., 2018).

Another limitation concerns the fact that the SH condition
was not assisted. It is likely that assisted SH could yield better
treatment results (Andersson et al., 2012, 2015). Furthermore, it
is unclear what effect the B4DT would have for patients who have
been treated with assisted SH. Although the study included all
consecutive referrals to the clinic, there might, however, be noted
that during the referral period there was an ongoing national
study that targeted specifically patients with OCD that previously
had received CBT. Another limitation concerns the unbalanced
gender distribution. Furthermore, which components of the
4-day format that can be seen as critical for outcome was
not the focus of the current study. However, future research
should consider comparing the B4DT with the same treatment
delivered across 12 weeks with a single therapist and individual
treatment given in the 4-day format. This could allow for
inferences concerning specific components of the treatment such
as the concentration of the treatment and the effects of working
in groups.”

The results from this RCT provide evidence that most OCD
patients treated with B4DT, delivered at another site than
the originators’ clinic, achieve highly comparable outcomes at
post-treatment and 3-month follow-up, as a number of open
trials have reported (Haven et al., 2014, 2017; Hansen et al.,
2018; Kvale et al., 2018; Davíðsdóttir et al., 2019; Launes
et al., 2019a,b). In addition, the study replicated previous

| Item                  | Satisfaction rating |
|-----------------------|---------------------|
| Quality of service    | 1 2 3 4             |
| Kind of service       | 1 2 3 4             |
| Met needs             | 1 2 3 4             |
| Recommend to friend   | 1 2 3 4             |
| Amount of help        | 1 2 3 4             |
| Dealt with problems   | 1 2 3 4             |
| Overall satisfaction  | 1 2 3 4             |
| Come back             | 1 2 3 4             |

N = 25. Items are scored on a scale from 1 (low satisfaction) to 4 (high satisfaction).
findings concerning refusal and attrition rates. Replication studies on the B4DT format are needed from other sites, countries and cultures.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

The trial received ethical approval from the Regional Committee for Research Ethics (REK Vest, 2016/794) and was registered in ClinicalTrials.gov (Identifier: NCT02886780). Patients still in need of treatment after the SH intervention and the WL, were for ethical reasons granted participation in a B4DT group if they wanted. Also, the length of the SH and WL conditions were not longer than the ordinary waiting period at the clinic at the time when the trial was initiated. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

GK, L-GÖ, BH, KH, and GL contributed to the study design. GL and KH contributed to the data collection. All authors contributed to the statistical analysis, interpretation of the data, and drafting of the manuscript, and approved the final version.

REFERENCES

Abramowitz, J. S., Deacon, B. J., Olatunji, B. O., Wheaton, M. G., Berman, N. C., Losardo, D., et al. (2010). Assessment of obsessive-compulsive symptom dimensions: development and evaluation of the dimensional obsessive-compulsive symptom scale. Psychol. Assess. 22, 180–198. doi: 10.1037/a0018260

American Psychiatric and Association (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th Edn. Arlington, VA: American Psychiatric Publishing.

Andersson, E., Enander, J., and Andrén, P. (2012). Internet-based cognitive behaviour therapy for obsessive-compulsive disorder: a randomized controlled trial. Psychol. Med. 42, 2193–2203. doi: 10.1017/S003329171200244

Andersson, E., Hedman, E., and Enander, E. (2015). D-cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants A randomized clinical trial. JAMA Psychiatry 72, 659–667. doi: 10.1001/jamapsychiatry.2015.0546

Beard, C., and Bjorgvinsson, T. (2014). Beyond generalized anxiety disorder: psychometric properties of the GAD-7 in a heterogeneous psychiatric sample. J. Anxiety Disord. 28, 547–552. doi: 10.1016/j.janxdis.2014.06.002

Davíðsdóttir, S. D., Sigurjónsdóttir, O., Ludvígsdóttir, S. J., Hansen, B., Laukvik, I. L., Hagen, K., et al. (2019). Implementation of the Bergen 4-day treatment for OCD in Iceland. Clin. Neuropsychiatry 16, 33–38.

Eilertsen, T., Hansen, B., Kvale, G., Abramowitz, J. S., Holm, S. E. H., and Solem, S. (2017). The dimensional obsessive-compulsive scale: development and validation of a short form (DOCS-SF). Front. Psychol. 8:1503. doi: 10.3389/fpsyg.2017.01503

First, M. B., Williams, J. B. W., Karg, R. S., and Spitzer, R. L. (2015). Structured Clinical Interview for DSM-5 Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV), Arlington, VA: American Psychiatric Association.

Foa, E. B., Huppert, J. D., Leiberg, S., Langner, R., Kichic, R., Hajcak, G., et al. (2002). The Obsessive-Compulsive Inventory: development and validation of a short version. Psychol. Assess. 14, 485–496. doi: 10.1037/1040-3590.14.4.485

Gilliam, C. M., Diefenbach, G. J., Whiting, S. E., and Tolin, D. F. (2010). Stepped care for obsessive-compulsive disorder: an open trial. Behav. Res. Therapy 48, 1144–1149. doi: 10.1016/j.brat.2010.07.010

Goodman, W. K., Price, L. H., Rasmussen, S. A., Mazure, C., Delgado, P., Heninger, G. R., et al. (1989a). The Yale-Brown Obsessive Compulsive Scale. II. validity. Arch. Gen. Psychiatry 46, 1012–1016. doi: 10.1001/archpsyc.1989.01810110054008

Goodman, W. K., Price, L. H., Rasmussen, S. A., Mazure, C., Fleischmann, R. L., Hill, C. L., et al. (1989b). The Yale-Brown Obsessive Compulsive Scale. I. development, use, and reliability. Arch. Gen. Psychiatry 46, 1006–1011. doi: 10.1001/archpsyc.1989.01810110048007

Hansen, B., Hagen, K., Øst, L. G., Solem, S., and Kvale, G. (2018). The Bergen 4-day OCD treatment delivered in a group setting: 12-month follow-up. Front. Psychol. 9:639. doi: 10.3389/fpsyg.2018.00639

Hansen, B., Kvale, G., Hagen, K., Havnen, A., and Øst, L. G. (2019). The Bergen 4-day treatment for OCD: four years follow-up of concentrated ERP in a clinical mental health setting. Cogn. Behav. Ther. 48, 89–105. doi: 10.1080/16506073.2018.1478447

Havnen, A., Hansen, B., Øst, L. G., and Kvale, G. (2014). Concentrated ERP delivered in a group setting: an effectiveness study. J. Obsess. Compul. Relat. Disord. 3, 319–324. doi: 10.1016/j.joclr.2014.08.002

Havnen, A., Hansen, B., Øst, L. G., and Kvale, G. (2017). Concentrated ERP delivered in a group setting: a replication study. Behav. Cogn. Psychother. 45, 530–536. doi: 10.1017/S1352465817000091

Jonsson, H., Kristensen, M., and Arendt, M. (2015). Intensive cognitive behavioural therapy for obsessive-compulsive disorder: a systematic review and meta-analysis. J. Obsessive Compuls. Relat. Disord. 6, 83–96. doi: 10.1016/j.joclr.2015.04.004

Kroenke, K., Spitzer, R. L., Williams, J. B., and Lowe, B. (2010). The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen. Hosp. Psychiatry 32, 345–359. doi: 10.1016/j.genhosppsych.2010.03.006

Kvale, G., and Hansen, B. (2014). Dissemination and intensifying evidence-based treatment for OCD: Norway is in the lead. Nordic Psychiatr. 3, 14–15.

Kvale, G., Hansen, B., Bjorgvinsson, T., Bortveit, T., Hagen, K., Haseth, S., et al. (2018). Successfully treating 90 patients with obsessive compulsive disorder in eight days: the Bergen 4-day treatment. BMC Psychiatry 18:323. doi: 10.1186/s12888-018-1887-4

Larsen, D. L., Attkisson, C. C., Hargreaves, W. A., and Nguyen, T. D. (1979). Assessment of client/patient satisfaction: development of a general scale. Eval. Program Plann. 2, 197–207. doi: 10.1016/0149-7189(79)90094-6

Launes, G., Laukvik, I. L., Sunde, T., Klovning, L., Hagen, K., Solem, S., et al. (2019a). The Bergen 4-day treatment for obsessive-compulsive disorder: does it work in a new clinical setting? Front. Psychol. 10:1069. doi: 10.3389/fpsyg.2019.01069

Launes, G., Sunde, T., Øst, L. G., Klovning, L., Laukvik, I. L., Himle, J., et al. (2019b). A randomized controlled trial of concentrated ERP for obsessive-compulsive disorder: the Bergen 4-day treatment (B4DT). Front. Psychol. 10:2500. doi: 10.3389/fpsyg.2019.02500

Mataix-Cols, D., Fernandez de la Cruz, L., Nordsletten, A. E., Lenhard, F., Isomura, K., and Simpson, H. B. (2016). Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. World Psychiatry 15, 80–81. doi: 10.1002/wps.2299

Mundahl Engels, J., and Diehr, P. (2003). Imputation of missing longitudinal data: a comparison of methods. J. Clin. Epidemiol. 56, 968–976. doi: 10.1016/S0895-4356(03)00170-7

National Institute for Health and Care Excellence [NICE] (2005). Obsessive-Compulsive Disorder and Body Dysmorphic Disorder: Treatment. London: NICE.

Nguyen, T. D., Attkisson, C. C., and Stegner, B. L. (1983). Assessment of patient satisfaction: development and refinement of a service evaluation questionnaire. Eval. Progr. Plann. 6, 299–313. doi: 10.1016/0149-7189(83)90010-1
Launes, B. O., Davis, M. L., Powers, M. B., and Smits, J. A. (2013). Cognitive-behavioral therapy for obsessive-compulsive disorder: a meta-analysis of treatment outcome and moderators. *J. Psychiatr. Res.* 47, 33–41. doi: 10.1016/j.jpsychires.2012.08.020

Öst, L.-G., Havnen, A., Hansen, B., and Kvale, G. (2015). Cognitive behavioral treatments of obsessive-compulsive disorder. A systematic review and meta-analysis of studies published 1993-2014. *Clin. Psychol. Rev.* 40, 156–169.

Öst, L.-G., and Ollendick, T. H. (2017). Brief, intensive and concentrated cognitive behavioral treatments for anxiety disorders in children: a systematic review and meta-analysis. *Behav. Res. Ther.* 97, 134–145. doi: 10.1016/j.brat.2017.07.008

Pearcy, C. P., Anderson, R. A., Egan, S. J., and Rees, C. S. (2016). A systematic review and meta-analysis of self-help therapeutic interventions for obsessive-compulsive disorder: is therapeutic contact key to overall improvement? *J. Behav. Therapy Exp. Psychiatry* 51, 74–83.

Rosa-Alcázar, A. I., Sánchez-Meca, J., Gómez-Conesa, A., and Martín-Martínez, F. (2008). Psychological treatment of obsessive–compulsive disorder: a meta-analysis. *Clin. Psychol. Rev.* 28, 1310–1325.

Rutter, L. A., and Brown, T. A. (2017). Psychometric properties of the generalized anxiety disorder scale-7 (GAD-7) in outpatients with anxiety and mood disorders. *J. Psychopathol. Behav. Assess.* 39, 140–146. doi: 10.1007/s10862-016-9571-9

Shafran, R., Clark, D. M., Fairburn, C. G., Arntz, A., Barlow, D. H., Ehlers, A., et al. (2009). Mind the gap: improving the dissemination of CBT. *Behav. Res. Ther.* 47, 902–909. doi: 10.1016/j.brat.2009.07.003

Solem, S., Hjemdal, O., Vogel, P. A., and Stiles, T. C. (2010). A Norwegian version of the Obsessive-Compulsive Inventory–Revised: psychometric properties. *Scand. J. Psychol.* 51, 509–516. doi: 10.1111/j.1467-9450.2009.00798.x

Spitzer, R. L., Kroenke, K., Williams, J. B., and Lowe, B. (2006). A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch. Intern. Med.* 166, 1092–1097. doi: 10.1001/archinte.166.10.1092

Tolin, D. F., Diefenbach, G. J., and Gilliam, C. M. (2011). Stepped care versus standard cognitive-behavioral therapy for obsessive-compulsive disorder: a preliminary study of efficacy and costs. *Depress. Anxiety* 28, 314–323. doi: 10.1002/da.20804

Tolin, D. F., Diefenbach, G. J., Maltby, N., and Hannan, S. E. (2005). Stepped care for obsessive-compulsive disorder: a pilot study. *Cogn. Behav. Pract.* 12, 403–414.

Veale, D., Naismith, I., Miles, S., Gledhill, L. J., Stewart, G., and Hodsoll, J. (2016). Outcomes for residential or inpatient intensive treatment of obsessive-compulsive disorder: a systematic review and meta-analysis. *J. Obsessive Compuls. Relat. Disord.* 8, 38–49. doi: 10.1016/j.jocrd.2015.11.005

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Launes, Hagen, Öst, Solem, Hansen and Kvale. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.